Poster Presentation Australasian Society for Dermatological Research Annual Scientific Meeting 2017

Development of a low-cost and minimally invasive absorbent microbiopsy for skin and blood sampling (#45)

Benson U Wang Lei 1 , Li Lin 1 , Miko Yamada 1 2 , Tarl Prow 1 2
  1. University of Queensland, Woolloongabba, QUEENSLAND, Australia
  2. Future Industries Institute, University of South Australia, Adelaide, SA, Australia

The goal of this study is to address the unmet clinical need of a rapid and controlled micro-extraction method for precise blood and skin sampling. With laser cutting and 3D printing technologies, we are developing a minimally invasive skin and blood sampling device, absorbent microbiopsy, with medical-grade materials, aiming to facilitate the molecular detection of early signs of skin diseases. We hypothesize that the absorbent microbiopsy can provide a diagnostic platform for blood and skin sampling in a painless and cost-effective manner for epidemiological studies in low resource regions. Due to its simple design, our device can be fabricated at a low cost (>A$10) and assembled in-house in under 5 min. The microneedle of our device is 1500µm x 500µm x 270µm in geometry (length x width x thickness), and the application velocity was determined to be 20 m/s. Preliminary data suggested that our device was able to collect blood samples and small pieces of skin tissue. X-ray imaging data showed that the device penetrated ~1 mm into the skin. In addition, qPCR experiment demonstrated that 1.39±0.90 ng of RNA was collected (n=5). Both blood markers, CD3 and CD19, and skin markers, KRT14 and TYR, were detected, and the four markers displayed 2.22, 9.06, 1.18 and 6.91-fold increase, respectively. Though there’s variation in blood absorption, it is expected that the limitation can be overcome by optimizing the application methodology and absorbent matrix. Moreover, a large-scale clinical study is highly desired in order to evaluate the reproducibility and reliability of our device. Once these issues are addressed, the device has the potential to offer a low-cost, simple and standardized molecular diagnostic platform for early disease detection as an alternative to the existing approach.

  • Are you currently a student: Yes
  • Are you currently a student: Yes